shisal1a Antibody

What is SHISAL1 and what cellular functions does it serve?

SHISAL1 (Protein shisa-like-1), also known as KIAA1644, is a single-pass type I membrane protein that localizes to cellular membranes. It functions as a transmembrane protein with potential roles in cellular signaling pathways. The protein is encoded by the SHISAL1 gene (Gene ID: 85352) and has the UniProt ID SHSL1_HUMAN . Current research indicates it may be involved in developmental processes, though more studies are needed to fully elucidate its specific molecular functions.

What types of SHISAL1 antibodies are available for research applications?

Commercially available SHISAL1 antibodies include polyclonal rabbit antibodies that target specific epitopes, such as the amino acid region 100-150. These antibodies are typically unconjugated IgG isotypes and are suitable for multiple applications including Western Blot (WB), enzyme-linked immunosorbent assay (ELISA), and immunohistochemistry (IHC) . Both monoclonal and polyclonal options exist, though polyclonal antibodies may provide broader epitope recognition, which can be advantageous when studying proteins with potential isoforms or post-translational modifications.

What are the recommended applications for SHISAL1 antibodies?

SHISAL1 antibodies have been validated for several research applications:

• Western Blot (WB): Typically used at dilutions of 1:500-2000

• Immunohistochemistry (IHC-P): Effective at dilutions of 1:50-300

• ELISA: Recommended dilutions range from 1:2000-20000

The choice of application should be determined by your specific research questions. Western blotting is ideal for protein size verification and semi-quantitative analysis, while IHC provides valuable information about spatial protein distribution within tissues.

What is the recommended storage and handling protocol for SHISAL1 antibodies?

To maintain antibody integrity and functionality:

• Store at -20°C for up to 1 year from the date of receipt

• Avoid repeated freeze-thaw cycles that can compromise antibody performance

• The antibody is typically supplied in liquid PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide

• Working dilutions should be prepared fresh and can typically be stored at 4°C for short periods (1-2 weeks)

How can I validate the specificity of a SHISAL1 antibody for my experimental system?

Antibody validation is critical for ensuring experimental rigor. A comprehensive validation approach should include:

• Positive and negative controls: Use tissues/cells known to express or lack SHISAL1

• Genetic knockdown/knockout: Compare antibody reactivity in wild-type vs. SHISAL1-depleted samples

• Peptide competition assays: Pre-incubation with the immunizing peptide should abolish specific signals

• Cross-species reactivity testing: Verify reactivity across relevant model organisms (the antibody shows reactivity to human and mouse SHISAL1)

• Cross-validation with multiple antibodies: Use antibodies targeting different SHISAL1 epitopes

This multi-pronged approach helps mitigate the risk of misinterpretation due to antibody cross-reactivity, which is a recognized contributor to the reproducibility crisis in research .

What are the optimal conditions for Western blot analysis using SHISAL1 antibodies?

For optimal Western blot results with SHISAL1 antibodies:

• Sample preparation: Use appropriate lysis buffers containing protease inhibitors

• Protein loading: 20-50 μg of total protein per lane is typically sufficient

• Separation: 10-12% SDS-PAGE gels are recommended for optimal resolution

• Transfer: PVDF membranes often provide better results than nitrocellulose for this protein

• Blocking: 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature

• Primary antibody: Dilute 1:500-2000 in blocking buffer and incubate overnight at 4°C

• Secondary antibody: Anti-rabbit HRP conjugates typically at 1:5000-10000 dilution

• Detection: Both chemiluminescence and fluorescence-based methods are suitable

Optimization may be required for your specific experimental system, particularly regarding antibody dilution and incubation time.

What controls should I include when performing IHC with SHISAL1 antibodies?

Proper controls are essential for IHC experiments:

• Positive tissue control: Use tissues known to express SHISAL1

• Negative tissue control: Use tissues known not to express SHISAL1

• Technical negative control: Omit primary antibody but include all other steps

• Isotype control: Use non-specific rabbit IgG at the same concentration

• Peptide competition control: Pre-incubate the antibody with the immunizing peptide

• Genetic control: If available, use tissues from knockout models

These controls help distinguish specific staining from background or non-specific signals, which is particularly important when interpreting membrane protein localization.

How can I address potential cross-reactivity issues with SHISAL1 antibodies?

Cross-reactivity is a significant concern that can lead to data misinterpretation. To address this issue:

• Perform bioinformatic analyses to identify proteins with sequence similarity to SHISAL1

• Test antibody reactivity in systems expressing potential cross-reactive proteins

• Use epitope-specific antibodies targeting unique regions of SHISAL1

• Implement orthogonal detection methods (e.g., mass spectrometry) to confirm findings

• Consider genetic approaches (siRNA, CRISPR) to validate antibody specificity

As highlighted in recent literature, even well-characterized antibodies can exhibit unexpected cross-reactivity due to epitope sharing across unrelated proteins . This is particularly important when studying membrane proteins like SHISAL1, where accessibility of epitopes may be affected by protein conformation and membrane integration.

What are the considerations for using SHISAL1 antibodies in multiplex immunoassays?

Multiplexed detection presents additional challenges that require careful consideration:

• Antibody compatibility: Ensure primary antibodies are from different host species to avoid cross-reactivity with secondary detection systems

• Fluorophore selection: Choose fluorophores with minimal spectral overlap to reduce bleed-through

• Signal optimization: Balance signal intensity across targets to prevent dominant signals from obscuring weaker ones

• Sequential staining: Consider sequential rather than simultaneous antibody incubations for challenging combinations

• Validation: Validate multiplex protocols against single-plex controls to ensure comparable sensitivity and specificity

Multiplex approaches can provide valuable contextual information about SHISAL1 localization relative to other cellular markers but require rigorous optimization and validation .

How might genetic variations in SHISAL1 affect antibody binding and experimental interpretation?

Genetic variation presents a significant challenge for antibody-based detection systems:

• Single nucleotide polymorphisms (SNPs) or other genetic variations in SHISAL1 may alter epitope sequences recognized by antibodies

• Such variations can result in false negatives if they disrupt antibody binding sites

• Population differences in SHISAL1 variants may lead to inconsistent results across sample cohorts

• Monoclonal antibodies are particularly vulnerable to epitope alterations, potentially creating blind spots in detection

• Polyclonal antibodies may offer more robust detection across variants but with potential specificity trade-offs

Recent research underscores how genetic variations in target proteins can compromise antibody performance, leading to misinterpretation of experimental data . Researchers should consider known polymorphisms in SHISAL1 when interpreting unexpected results or discrepancies between detection methods.

What approaches can be used to quantify SHISAL1 expression levels in complex biological samples?

Accurate quantification requires careful methodology:

• Multiple internal controls: Include housekeeping proteins with similar expression levels to SHISAL1

• Standard curves: When possible, use recombinant SHISAL1 proteins for calibration

• Digital image analysis: Employ software tools with appropriate algorithms for band quantification

• Normalization strategies: Normalize to total protein loading (e.g., using stain-free gels) rather than single housekeeping proteins

• Statistical validation: Apply appropriate statistical methods to assess significance of observed differences

For ELISA-based quantification, standard curves should be prepared using recombinant SHISAL1 protein, and samples should be analyzed at multiple dilutions to ensure measurements fall within the linear range of detection .

What are common causes of weak or absent signals when using SHISAL1 antibodies?

Several factors can contribute to poor signal detection:

• Protein expression levels: SHISAL1 may be expressed at low levels in some tissues or cell types

• Epitope accessibility: Membrane proteins like SHISAL1 may have epitopes masked by membrane structures or protein folding

• Fixation artifacts: Overfixation can mask epitopes in fixed tissues or cells

• Antibody quality: Degradation due to improper storage or handling

• Protocol parameters: Suboptimal antibody concentration, incubation time, or detection system

• Target degradation: Inadequate protease inhibition during sample preparation

Optimization strategies include testing different antibody concentrations, extending incubation times, using signal amplification methods, and comparing different epitope retrieval techniques for fixed samples .

How can I optimize antigen retrieval for SHISAL1 detection in fixed tissue samples?

Effective antigen retrieval is critical for membrane proteins like SHISAL1:

• Heat-induced epitope retrieval (HIER): Test multiple buffer systems (citrate pH 6.0, EDTA pH 8.0, Tris-EDTA pH 9.0)

• Enzymatic retrieval: Consider mild protease digestion (trypsin, proteinase K) as an alternative

• Duration optimization: Test different HIER durations (10-30 minutes)

• Combined approaches: Sequential application of HIER followed by brief enzymatic treatment

• Detergent incorporation: Addition of mild detergents (0.05% Tween-20) to retrieval buffers may improve accessibility of membrane proteins

The optimal retrieval method should be determined empirically for each tissue type and fixation protocol, as overly aggressive retrieval can damage tissue morphology while insufficient retrieval leads to weak signals .

What strategies can address non-specific background when using SHISAL1 antibodies?

High background can obscure specific signals and complicate interpretation:

• Blocking optimization: Test different blocking agents (BSA, non-fat milk, normal serum, commercial blockers)

• Antibody dilution: Increase primary and/or secondary antibody dilutions

• Washing stringency: Increase wash duration and/or detergent concentration

• Tissue preparation: Ensure complete deparaffinization and hydration of fixed tissues

• Endogenous enzyme inactivation: Block endogenous peroxidase or phosphatase activity

• Avidin/biotin blocking: For biotin-based detection systems, block endogenous biotin

• Fc receptor blocking: In immune tissues, block Fc receptors that may bind antibodies non-specifically

The choice of blocking solution should be optimized for each application, as the effectiveness can vary depending on the specific antibody and sample type .

How can I distinguish between SHISAL1 isoforms or post-translational modifications?

Distinguishing protein variants requires careful analytical approaches:

• High-resolution gel systems: Use gradient gels or Phos-tag™ acrylamide for improved separation

• Isoform-specific antibodies: Use antibodies targeting unique regions of specific isoforms

• Combined immunoprecipitation and mass spectrometry: For definitive identification of variants

• Phosphatase treatment: To distinguish phosphorylated from non-phosphorylated forms

• 2D gel electrophoresis: To separate variants based on both molecular weight and isoelectric point

For SHISAL1, which is a membrane protein, sample preparation techniques that effectively solubilize the protein without disrupting important modifications are particularly important .

What approaches can validate SHISAL1 antibody specificity in the context of genetic variation?

Genetic diversity necessitates thorough validation strategies:

• Sequence-based analysis: Compare antibody epitope sequences across known genetic variants

• Recombinant protein panels: Test antibody reactivity against recombinant proteins representing known variants

• Genotyped sample testing: Evaluate antibody performance across samples with known SHISAL1 genotypes

• Orthogonal validation: Correlate antibody-based detection with mRNA expression or genetic tagging

• Mixed antibody approaches: Use antibody cocktails targeting multiple epitopes to ensure detection across variants

As highlighted in recent literature, genetic variation can significantly impact antibody performance, potentially leading to false negatives or positives that complicate data interpretation .

How should I approach contradictory results between different SHISAL1 detection methods?

Discrepant results require systematic troubleshooting:

• Technical validation: Repeat experiments with appropriate controls to confirm reproducibility

• Method-specific artifacts: Evaluate each method for known limitations (e.g., epitope masking in fixed tissues)

• Antibody characteristics: Consider epitope locations and accessibility in different experimental contexts

• Sample preparation effects: Test if different sample preparation methods affect protein detection

• Quantitative comparison: Perform correlation analyses between methods across multiple samples

• Orthogonal validation: Implement non-antibody-based methods (e.g., mass spectrometry, RNA-seq)

Discrepancies between methods may reflect biological reality rather than technical artifacts, potentially revealing important insights about protein conformation, localization, or modification states .